Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 USD | +1.77% | +6.05% | +9.02% |
09/05 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.02% | 1.98Cr | |
+4.90% | 11TCr | |
+10.85% | 11TCr | |
-12.27% | 2.23TCr | |
-3.00% | 2.19TCr | |
-5.80% | 1.86TCr | |
-36.52% | 1.81TCr | |
-9.51% | 1.7TCr | |
+3.66% | 1.37TCr | |
+36.98% | 1.24TCr |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise